WASHINGTON (Reuters) - Misleading research is often published in major medical journals and doctors are lending their names to it, the editor of the Journal of the American Medical Association said on Tuesday.
Doctors, regulators, publishers and others are all taking money, information and small presents from pharmaceutical companies and being influenced in the process, said Dr. Catherine DeAngelis.
"It goes for all of us," DeAngelis, whose journal is influential nationally and globally, said in a telephone interview.
Her journal, commonly known as JAMA, published a paper accusing Merck and Co. of suppressing data that showed its now-withdrawn pain drug Vioxx was harming patients, and saying that academic researchers had lent credibility to the company's allegedly manipulated research by putting their names on the work.
Merck and the independent researchers have denied this and say the journal is mistaken in this case.
But DeAngelis said there is a "gigantic" problem of drug companies influencing doctors and patients. Her journal presents the Merck case as a specific example of one facet of the problem.
"We have given away our profession and we have got to take it back," she said.
Drug companies spend millions of dollars on promotional materials, from pens to prescription pads. They pay for doctors to travel to seminars, often in exotic places, to learn about drugs.
They set up elaborate booths at medical meetings and send articulate drug representatives and "detailers" to pay personal visits to doctors.
CAREFUL WATCHDOGS
"Physicians in private practice shouldn't even take a pen from anybody, let alone pizza lunches or whatever," DeAngelis said.
In addition, the companies fund many medical studies. Government funds are usually only used for the first stages of research -- the rest is left to companies who conduct studies to seek licensing for various drugs. DeAngelis said there is no way around this.
But, she added, "The editors (of medical journals) have to be very, very careful watchdogs over what we publish."
